期刊文献+

基于肿瘤特征的抗肿瘤中药药理学机制探析 被引量:16

Exploration on Pharmacological Mechanism of Chinese Medicines Targeting Cancer Hallmarks
暂未订购
导出
摘要 目的:基于肿瘤特征的抗肿瘤中药药理机制研究进展和有关研究标准化的问题。方法:检索PubMed,CNKI,重庆维普,百链云图书馆、读秀学术搜索网上数据库,针对肿瘤特征,将抗肿瘤中药药理学机制研究进行归纳总结。结果:基于肿瘤特征的抗肿瘤中药药理学机制研究可分为11大类:抗增殖信号维持、抗生长抑制逃避、增强免疫、抗无限复制、抗癌性促炎反应、抗侵袭转移、抗血管生成、抗基因组不稳定与突变、抗细胞死亡抵抗、抗细胞能量代谢失衡、抗肿瘤干细胞。结论与展望:基于肿瘤特征的抗肿瘤中药药理学机制分类方法有利于中药抗肿瘤的标准化研究,值得推广。并随着对肿瘤特征研究的深入,中药针对这些特征的研究必将随之发展。 Objective: To review the research progress of anticancer Chinese medicines(CMs) based on the hallmarks of cancer and discuss guideline for anticancer CMs. Methods: PubMed, CNKI, Chongqing VIP, Bailianyun Library, Duxiu Scholar online databases were retrieved. The mechanisms of CMs for anti-cancer were summarized. Results: The underlying mechanisms of Chinese medicines against cancer were divided into 11 categories by targeting: sustaining proliferative signaling, evading growth suppressor, avoiding immune destruction, enabling replicative immortality, tumorpromoting inflammation, activating invasion metastasis, inducing angiogenesis, genome instability & mutation, resisting cell death, deregulating cellular energetics, and cancer stem cells. Conclusion and Prospectives: The categories for CMs based on cancer hallmarks may facilitate the research standardization of CMs Pharmacology, which deserves further application. With the deepening of research on hallmarks of cancer, the research on these characteristics of Traditional Chinese Medicine will surely develop.
作者 汪选斌 李洪亮 李明伦 冯奕斌 Wang Xuanbin;Li Hongliang;Li Minglun;Feng Yibin(Hubei Key Laboratory of Wudang Local Chinese Medicine Research , Hubei University of Medicine,Shiyan 442000, China;Department of Radiation Oncology, University Hospital, LMU Munich, Munich 81377,Germany;School of Chinese Medicine, The University of Hong Kong, Hong Kong, China)
出处 《世界科学技术-中医药现代化》 CSCD 北大核心 2019年第1期25-32,共8页 Modernization of Traditional Chinese Medicine and Materia Medica-World Science and Technology
基金 国家自然基金委员会面上项目(81784356):基于SREBP1通路探讨制何首乌对肝癌脂代谢的抑制机制 负责人:李洪亮 武当特色中药研究湖北省重点实验室开放课题重点项目(WDCM001):小檗碱对肝癌细胞Cyclin D1转录后降解的诱导作用及机制研究 负责人:冯奕斌 湖北医药学院自由探索基金重点创新团队项目(2018YH KT01):武当抗肿瘤中药研究 负责人:汪选斌
关键词 中药 肿瘤特征 中药药理学 机制 综述 Chinese medicines cancer hallmark Chinese medicines pharmacology mechanisms review
  • 相关文献

参考文献37

二级参考文献388

共引文献416

同被引文献290

引证文献16

二级引证文献158

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部